Yes, Levemir (insulin detemir) is being discontinued. Novo Nordisk, the manufacturer, is phasing out both Levemir Penfill and Levemir FlexPen as part of a broader portfolio consolidation. The company has stated that this decision has nothing to do with safety or quality concerns. Supply is expected to remain available through the end of 2026, giving patients and healthcare providers time to plan a transition.
Why Novo Nordisk Is Discontinuing Levemir
Novo Nordisk’s official explanation is straightforward: the company is consolidating its insulin portfolio to ensure stable product supply across its remaining lines. Levemir, while effective, is an older long-acting insulin that has been largely overshadowed by newer options. With the availability of more advanced basal insulins like Tresiba (insulin degludec) and competitors like Toujeo (insulin glargine U-300), manufacturers have already scaled back promotion of detemir in recent years. Discontinuing it frees up manufacturing capacity for products the company sees as its future.
What You Should Do Right Now
If you currently take Levemir, you don’t need to rush to your doctor’s office or call in an emergency prescription. Your healthcare provider should contact you within the next 12 months to discuss switching to an alternative insulin. Levemir won’t disappear from pharmacy shelves overnight; stock is expected to last through late 2026.
That said, there’s no harm in being proactive. If you have an upcoming appointment, it’s worth raising the topic so you and your provider can start thinking about which replacement makes the most sense for your situation. Don’t stockpile Levemir, as insulin has expiration dates and storage requirements that make hoarding impractical.
Alternative Basal Insulins
Several FDA-approved long-acting and ultra-long-acting insulins can replace Levemir. They fall into two main categories.
Insulin Glargine (Long-Acting)
Glargine U-100 is the most widely used basal insulin in the world, originally sold as Lantus by Sanofi. Multiple biosimilars are now available, including Basaglar, Semglee, and Rezvoglar, which tend to cost less than the brand-name version. Glargine provides roughly 24 hours of coverage with a relatively flat profile, similar to what Levemir offers. The dose conversion from detemir to glargine U-100 is generally 1:1 (unit for unit), though your provider may need to fine-tune the dose after the switch.
Ultra-Long-Acting Options
Two ultra-long-acting insulins offer even longer duration and flatter blood sugar control. Tresiba (insulin degludec), made by Novo Nordisk itself, lasts up to 42 hours and allows more flexibility in injection timing. Toujeo (insulin glargine U-300), made by Sanofi, is a concentrated version of glargine with a smoother profile than the standard U-100 formulation. Both are strong options for people who experience blood sugar variability overnight or who occasionally forget a dose. Switching from detemir to either of these typically starts at a 1:1 dose ratio, with adjustments based on blood sugar monitoring in the weeks that follow.
Switching During Pregnancy
Levemir has long been a preferred basal insulin during pregnancy, so its discontinuation raises a specific concern for people who are pregnant or planning to become pregnant. A meta-analysis of insulin analogs in pregnancy found that both detemir and glargine were safe treatment options, with similar rates of complications for mothers and babies compared to NPH insulin. Birth weights, rates of severe low blood sugar in the mother, and neonatal intensive care admissions were comparable across all three.
This means glargine is a reasonable replacement for Levemir during pregnancy. NPH insulin, an older intermediate-acting option, also remains safe and well-studied in pregnant patients. Your endocrinologist or maternal-fetal medicine specialist can help decide which fits best based on your blood sugar patterns and dosing schedule.
What the Transition Looks Like
Switching basal insulins is common and generally not complicated, but it does require attention in the first few weeks. Most providers will have you start the new insulin at the same total daily dose you were taking with Levemir. You’ll likely need to check your blood sugar more frequently during the transition period, especially fasting levels in the morning, to see whether the new insulin is covering you the same way.
One practical difference: if you were injecting Levemir twice a day (which some people need because detemir’s duration can fall short of 24 hours), you may be able to move to a single daily injection with glargine or degludec. That’s actually an upgrade in convenience. On the other hand, if your blood sugar control was excellent on Levemir with minimal effort, expect a brief adjustment period as you and your provider dial in the replacement dose.
Keep a log of your blood sugar readings for at least two to four weeks after switching. If you use a continuous glucose monitor, the data will make the transition even smoother, since your provider can see trends rather than relying on individual fingerstick values.